SEARCH:   Advanced

Blood, Vol. 109, Issue 5, 2165-2173, March 1, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling Blood Sin et al. 109: 2165 Supplemental materials for: Sin et al, Vol 109, Issue 5, 2165-2173 Files in this Data Supplement: Table S1. Cell-cycle changes after 4 days in 50 nM rapamycin (PDF, 12.5 KB) Table S2. Cytokine levels in picograms per milliliter (PDF, 16.3 KB) Figure S1. Rapamycin does not affect molecules that act upstream of mTOR in the Akt signaling pathway (JPG, 92.6 KB) - Shown is the luminogram of a Western blot analysis using the indicated antibodies and protein extract from BCBL-1 or BC-1 cells treated with 50 nM rapamycin or vehicle control. Molecular weight markers are indicated on the left. Figure S2. Rapamycin does not affect KSHV transcription (JPG, 76.8 KB) - The gray circles indicate relative levels for each of the KSHV mRNAs on a log2 scale (CT) at 48 hours after rapamycin (vertical axis) or mock (horizontal axis) treatment for BC-1 (upper panel) and BCBL-1 (lower panel) cells. The black diamonds indicate relative levels (CT) of nontemplate control (vertical axis) or mock-treated cells (horizontal axis). A CT = 40 indicates the absence of any signal after 40 cycles of PCR. The dotted 45-degree line designates identical mRNA levels under both conditions. mRNAs located above the line are repressed by rapamycin vis-à-vis mock treatment. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020